New administration model of trans-chalcone biodegradable polymers for the treatment of experimental leishmaniasis

Acta Tropica

Volumn 98, Issue 1, 2006, Pages 59-65

  Piñero, Jose ^a   Temporal, Rosane M ^b   Silva Gonçalves, Antonio J ^b   Jimenez I A ^a   Bazzocchi, Isabel L ^a   Oliva, Alexis ^a   Perera, Antonio ^c   Leon, Leonor L ^b   Valladares, Basilio ^a  

^a UNIVERSIDAD DE LA LAGUNA   (Spain)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Chemotherapy; Leishmania; PLA and PLGA implants; Trans chalcone

Indexed keywords

CHALCONE; GLYCOLIC ACID; PENTAMIDINE; POLYLACTIC ACID; POLYMER;

BIODEGRADATION; GROWTH RESPONSE; INHIBITION; LEISHMANIASIS; MICROBIAL ACTIVITY; PARASITIC DISEASE; PATHOGENICITY; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; BODY WEIGHT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GROWTH INHIBITION; IC 50; IMPLANT; IN VITRO STUDY; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM; LEISHMANIA TROPICA; LEISHMANIASIS; MALE; MOUSE; NONHUMAN; PARASITE; PATHOGENICITY; PROMASTIGOTE;

ABSORBABLE IMPLANTS; ANIMALS; ANTIPROTOZOAL AGENTS; CHALCONE; DRUG THERAPY, COMBINATION; LACTIC ACID; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; PENTAMIDINE; POLYGLYCOLIC ACID; POLYMERS; TIME FACTORS;

LEISHMANIA AMAZONENSIS; LEISHMANIA BRAZILIENSIS; LEISHMANIA INFANTUM; LEISHMANIA TROPICA;

EID: 33645946695     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2006.02.001     Document Type: Article

References (40)

1. Albrecht H., Sobottka I., Emminger C., Jablonowski H., Just G., Stoehr A., Kubin T., Salzberger B., Lutz T., and van Lunzen J. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch. Pathol. Lab. Med. 120 (1996) 189-198
2. Alves L.V., Temporal R.M., Cysne-Finkelstein L., and Leon L. Efficacy of a diarylheptanoid derivative against Leishmania amazonensis. Mem. Inst. Oswaldo Cruz 98 (2003) 553-555
3. Borst P., and Oullette M. New mechanisms of drug resistance in parasitic protozoa. Ann. Rev. Microbiol. 49 (1995) 427-460
4. Chang K.P., Reedb S.G., McGwirec B.S., and Soonge L. Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop. 85 (2003) 375-390
5. Chen M., Brøgger Christensen S., Zhai L., Rasmussen M.H., Theander T.G., Frøkjaer S., Steffansen B., Davidsen J., and Kharazmi A. The novel oxygenated chalcone, 2,4-dimethoxy-4′-butoxychalcone, exhibits potent activity against human malaria parasite Plasmodium falciparum in vitro and rodent parasites Plasmodium berghei and Plasmodium yoelii in vivo. J. Infect. Dis. 176 (1997) 1327-1333
6. Chen M., Christensen S.B., Theander T.G., and Kharazmi A. Antileishmanial activity of licochalcone A in mice infected with Leishmania major and in hamsters infected with Leishmania donovani. Antimicrob. Agents Chemother. 38 (1994) 1339-1344
7. Chen M., Zhai L., Christensen S.B., Theander T.G., and Kharazmi A. Inhibition of fumarate reductase in Leishmania major and L. donovani by chalcones. Antimicrob. Agents Chemother. 45 (2001) 2023-2029
8. Dereure J., Reynes J., Pratlong F., Lamaury I., Rioux J.A., Janbon F., and Dedet J.P. Visceral leishmaniasis in HIV-infected patients in the south of France. Bull. World Health Organ. 73 (1995) 245-246
9. Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans. Roy. Soc. Trop. Med. Hyg. 95 (2001) 239-243
10. Dey T., Anam K., Afrin F., and Ali N. Antileishmanial activities of stearylamine-bearing liposomes. Antimicrob. Agents Chemother. 44 (2000) 1739-1742
11. Eliaz R.E., and Kost J. Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins. J. Biomed. Mater. Res. 50 (2000) 388-396
12. Faraut-Gambarelli F., Piarroux R., Deniau M., Giusiano B., Marty P., Michel G., Faugere B., and Dumon H. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob. Agents Chemother. 41 (1997) 827-830
13. Friis-Moller A., Chen M., Fuursted K., Christensen S.B., and Kharazmi A. In vitro antimycobacterial and antilegionella activity of licochalcone A from Chinese licorice roots. Planta Med. 68 (2002) 416-419
14. Gallagher R.B., Marx J., and Hines P.J. Progress in Parasitology. Science 264 (1994) 1827
15. Gaspar R., Opperdoes F.R., Preat V., and Roland M. Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. Ann. Trop. Med. Parasitol. 86 (1992) 41-49
16. Go M.L., Liu M., Wilairat P., Rosenthal P.J., Saliba K.J., and Kirk K. Antiplasmodial chalcones inhibit sorbitol-induced hemolysis of Plasmodium falciparum-infected erythrocytes. Antimicrob. Agents Chemother. 48 (2004) 3241-3245
17. Hermoso A., Jiménez I.A., Mamani Z.A., Bazzocchi I.L., Piñero J.E., Ravelo A.G., and Valladares B. Antileishmanial activities of dihydrochalcones from Piper elongatum and synthetic related compounds. Structural requirements for activity. Bioorg. Med. Chem. 11 (2003) 3975-3980
18. Hirst S.I., and Stapley L.A. Parasitology: the dawn of a new millennium. Parasitol. Today 16 (2000) 1-3
19. Kayser O., and Kiderlen A.F. In vitro leishmanicidal activity of naturally occurring chalcones. Phytother. Res. 15 (2001) 148-152
20. Kwong A.K., Chou S., Sun A.M., Sefton M.V., and Goosen M.F.A. In vitro and in vivo release of insulin from poly(lactic acid) microbeads and pellets. J. Control. Release 4 (1986) 47-62
21. Langer R. Drug delivery and targeting. Nature 392 (1998) 5-10
22. Lee S.J., Park Y.J., Park S.N., Lee Y.M., Seol Y.J., Ku Y., and Chung C.P. Molded porous poly(l-lactide) membranes for guided bone regeneration with enhanced effects by controlled growth factor release. J. Biomed. Mater. Res. 55 (2001) 295-303
23. Lherm C., Couvreur P., Loiseau P., Bories C., and Gayral P. Unloaded polyisobutylcyanoacrylate nanoparticles: efficiency against bloodstream trypanosomes. J. Pharm. Pharmacol. 39 (1987) 650-652
24. Liu M., Wilairat P., Croft S.L., Tan A.L., and Go M.L. Structure-activity relationships of antileishmanial and antimalarial chalcones. Bioorg. Med. Chem. 11 (2003) 2729-2738
25. Lunardi F., Guzela M., Rodrigues A.T., Corrêa R., Eger-Mangrich I., Steindel M., Grisard E.C., Assreuy J., Calixto J.B., and Santos A.R.S. Trypanocidal and leishmanicidal properties of substitution-containing chalcones. Antimicrob. Agents Chemother. 47 (2003) 1449-1451
26. Medda S., Jaisankar P., Manna R.K., Pal B., Giri V.S., and Basu M.K. Phospholipid microspheres: a novel delivery mode for targeting antileishmanial agent in experimental leishmaniasis. J. Drug Target 11 (2003) 123-128
27. Montalban C., Calleja J.L., Erice A., Laguna F., Clotet B., Podzamczer D., Cobo J., Mallolas J., Yebra M., Gallego A., and The Co-operative Group for the Study of Leishmaniasis in AIDS. Visceral leishmaniasis in patients infected with human immunodeficiency virus. J. Infect. 21 (1990) 261-270
28. Nielsen S.F., Christensen S.B., Cruciani G., Kharazmi A., and Liljefors T. Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. J. Med. Chem. 41 (1998) 4819-4832
29. Piñero J.E., Martínez S., Del Castillo A., Portús M., and Valladares B. In vitro susceptibility of Leishmania infantum strains isolated from Spanish HIV-positive patients to Abelcet and Fungizone. J. Antimicrob. Chemother. 50 (2002) 304-306
30. Rivas L., Moreno J., Canavate C., and Alvar J. Virulence and disease in leishmaniasis: What is relevant for the patient?. Trends Parasitol. 20 (2004) 297-301
31. Rodrigues Jr. J.M., Croft S.L., Fessi H., Bories C., and Devissaguet J.P. The activity and ultrastructural localization of primaquine-loaded poly(d,l-lactide) nanoparticles in Leishmania donovani infected mice. Trop. Med. Parasitol. 45 (1994) 223-228
32. Rosenthal E., Marty P., Poizot-Martin I., Reynes J., Pratlong F., Lafeuillade A., Jaubert D., Boulat O., Dereure J., Gambarelli F., Gastaut J.A., Dujardin P., Dellamonica P., and Cassuto J.P. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans. Roy. Soc. Trop. Med. Hyg. 89 (1995) 159-162
33. Tachibana H., Yoshihara E., Kaneda Y., and Nakae T. In vitro lysis of the bloodstream forms of Trypanosoma brucei Fgambiense by stearylamine-bearing liposomes. Antimicrob. Agents Chemother. 32 (1988) 966-970
34. Torres-Santos E.C., Moreira D.L., Kaplan M.A., Meirelles M.N., and Rossi-Bergmann B. Selective effect of 2′, 6′-dihydroxy-4′-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis. Antimicrob. Agents Chemother. 43 (1999) 1234-1241
35. Torres-Santos E.C., Rodrigues J.M., Moreira D.L., Kaplan M.A., and Rossi-Bergmann B. Improvement of in vitro and in vivo antileishmanial activities of 2′,6′-dihydroxy-4′-methoxychalcone by entrapment in poly(d,l-lactide) nanoparticles. Antimicrob. Agents Chemother. 43 (1999) 1776-1778
36. Tsukiyama R., Katsura H., Tokuriki N., and Kobayashi M. Antibacterial activity of licochalcone A against spore-forming bacteria. Antimicrob. Agents Chemother. 46 (2002) 1226-1230
37. Venier-Julienne M.C., Vouldoukis I., Monjour L., and Benoit J.P. In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J. Drug Target. 3 (1995) 23-29
38. Yoshihara E., Tachibana H., and Nakae T. Trypanocidal activity of the stearylamine-bearing liposome in vitro. Life Sci. 40 (1987) 2153-2159
39. Zhai L., Blom J., Chen M., Christensen S.B., and Kharazmi A. The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob. Agents Chemother. 39 (1995) 2742-2748
40. Zhai L., Chen M., Blom J., Theander T.G., Christensen S.B., and Kharazmi A. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J. Antimicrob. Chemother. 43 (1999) 793-803